Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target dropped by stock analysts at Oppenheimer from $500.00 to $350.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price would suggest a potential upside of 72.63% from the company’s previous close.
A number of other brokerages also recently commented on ALNY. Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price for the company. Bank of America reduced their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Friday, July 10th. Finally, Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $428.05.
Read Our Latest Research Report on ALNY
Alnylam Pharmaceuticals Stock Down 1.3%
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business earned ($0.44) earnings per share. The firm’s revenue was up 96.4% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.
Institutional Trading of Alnylam Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the company. Norges Bank bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $895,816,000. Qube Research & Technologies Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $369,943,000. AQR Capital Management LLC increased its position in Alnylam Pharmaceuticals by 295.2% during the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after acquiring an additional 555,759 shares during the period. Orbis Allan Gray Ltd increased its position in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in Alnylam Pharmaceuticals by 2,221.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company’s stock worth $187,116,000 after purchasing an additional 392,668 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals News Roundup
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Alnylam reported second-quarter adjusted earnings of $1.84 per share, above the $1.63 consensus estimate, while revenue rose 66.9% year over year to $1.29 billion. The company also highlighted continued strength in its transthyretin (TTR) business. Alnylam quarterly earnings report
- Positive Sentiment: Analysts continue to see substantial long-term value despite lowering estimates. Stifel maintained a “buy” rating with a $318 price target, Needham retained “buy” with a $357 target, and Chardan reaffirmed “buy” with a $425 target. Analyst rating updates
- Neutral Sentiment: Alnylam’s 2026 revenue guidance is now $5.3 billion to $5.7 billion, broadly around the $5.6 billion analyst consensus, but the range and commentary indicate reduced confidence in near-term growth. Alnylam lowers 2026 outlook
- Neutral Sentiment: Several law firms announced securities-fraud investigations following the selloff. These announcements are generally shareholder-solicitation notices and do not establish wrongdoing, but they add headline and potential litigation risk. Securities fraud investigation announcement
- Negative Sentiment: Second-quarter revenue of $1.29 billion missed the $1.32 billion consensus, and another report placed EPS at $1.84 versus a $2.05 estimate. The combination of the revenue miss and lower Amvuttra/ATTR-CM expectations prompted multiple analysts to cut price targets, including Wells Fargo to $316 and Stifel to $318. Alnylam Amvuttra outlook article
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
- Peeling Out or Breaking Down? Ford’s High-Stakes Turnaround
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
